Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patient Convenience Study

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2015-11-05

Last Posted Date: 2019-02-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1852

Registration Number: NCT02597920

Locations: 🇧🇪
1160.247.1019 Boehringer Ingelheim Investigational Site, Braine-l'Alleud, Belgium
🇧🇪
1160.247.1018 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪
1160.247.1020 Boehringer Ingelheim Investigational Site, Brussels, Belgium

and more 145 locations

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Completed

Conditions: Venous Thromboembolism

First Posted Date: 2015-11-04

Last Posted Date: 2020-04-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7797

Registration Number: NCT02596230

Locations: 🇬🇷
University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece
🇭🇺
Dr. Kenessey Albert Kórház-Rendelõintézet, Balassagyarmat, Balassagyarmat, Hungary
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 219 locations

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin 10mg
Drug: empagliflozin 25 mg
Drug: Placebo

First Posted Date: 2015-10-28

Last Posted Date: 2019-01-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 65

Registration Number: NCT02589626

Locations: 🇯🇵
Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama, Japan
🇯🇵
Kubota Clinic, Kanagawa, Kawasaki, Japan
🇯🇵
Kunisaki Makoto Clinic, Fukuoka, Fukuoka, Japan

and more 13 locations

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2015-10-28

Last Posted Date: 2019-03-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 269

Registration Number: NCT02589639

Locations: 🇯🇵
Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya, Japan
🇯🇵
North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan
🇯🇵
Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku, Japan

and more 45 locations

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2015-10-20

Last Posted Date: 2018-11-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 977

Registration Number: NCT02580591

Locations: 🇺🇸
International Research Associates, LLC, Hialeah, Florida, United States
🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸
Sestron Clinical Research, Marietta, Georgia, United States

and more 186 locations

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

Phase 4

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Pirfenidone

First Posted Date: 2015-10-19

Last Posted Date: 2018-02-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 105

Registration Number: NCT02579603

Locations: 🇺🇸
Western CT Medical Group, P.C., Danbury, Connecticut, United States
🇫🇷
HOP Avicenne, Bobigny, France
🇫🇷
HOP de la Cavale Blanche, Brest, France

and more 20 locations

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin
Drug: Metformin

First Posted Date: 2015-10-16

Last Posted Date: 2016-11-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02577315

Locations: 🇷🇺
1276.27.001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation

DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin
Drug: Metformin HCl
Drug: Furosemide

First Posted Date: 2015-10-14

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02574845

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mucosolvan ® adult syrup
Drug: Ambroxol hydrochloride soft pastille

First Posted Date: 2015-10-09

Last Posted Date: 2015-12-31

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02572609

Actual Use Study of Tamsulosin in Men

Phase 3

Completed

Conditions: Urological Manifestations

Interventions: Drug: tamsulosin hydrochloride

First Posted Date: 2015-10-09

Last Posted Date: 2020-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1117

Registration Number: NCT02573311

Locations: 🇺🇸
Kroger Pharmacy #342, Cary, North Carolina, United States
🇺🇸
Garden Drug, Fort Lauderdale, Florida, United States
🇺🇸
Eagle Pharmacy, Houston, Texas, United States

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy